What your peers say about the optomap

Read what the media says

Click below to launch video

Michael Gorin, M.D.

Scott Oliver, M.D.

“Usually we approach angiography as a mundane necessity.  Now, I perform the the procedure much more enthusiastically, because the findings may be surprising.  The technology provides me with almost every type of angiography I might need, including closer looks at macular disorders or macular edema, while also helping me document peripheral disorders as well.”

Thomas R. Friberg, MD, MS
FACS of University of Pittsburgh
Pittsburgh, PA

“By using ultra-fluorescein angiography, we can more effectively identify peripheral pathology in retinal vascular disease.  The ultra-widefield technology provides the view we need to provide our patients with better care.”

Scott C. N. Oliver, MD
Rocky Mountains Lion Eye Institute
University of Colorado
Denver, CO

“I believe this technology will have a dramatic impact on our field, possibly as great as the impact OCT has had during the past 5 to 10 years.”

“After using it for several months, we realized that this technology provides diagnostic and therapeutic opportunities that have not been available through the use of fundus cameras and traditional imaging, so we decided the Optos P200MA platform was a good acquisition for our practice.  It is a bonus that patients really like the system, mainly because it is a noncontact system.”

Thomas Stone, MD
Retina Associates of Kentucky
Lexington, KY

“Ultra-widefield angiography has provided us with the ability to reliably obtain information about the retinovascular status of the periphery, namely the extent of nonperfusion and presence of vascular abnormalities or vascular leakage.”

“To be able to see the retina functionality during an angiogram improves the ophthalmologist’s ability to detect, treat and understand the biologic basis of the disease process.”

Ivan J. Suner, MD
Retina Associates of Florida
Tampa, FL

“Advantages of Ultra-widefield FA: 1. Precise diagnosis, 2. Objective measurement of disease severity, 3. Objective measurement of disease progression, 4. Increased precision and accuracy of treatment planning and outcome monitoring. It makes our laser treatment less of a hammer, and more of a drug that we can titrate.”

“Optos’ technology has changed the way we diagnose and thus potentially will change the way we treat diabetic retinopathy - this is truly revolutionary technology with game changing potential.”

Steven Schwartz, MD
Jules Stein, UCLA
Los Angeles, CA